AIMS: Differentiating endometrioid adenocarcinoma (EAC) from uterine serous carcinoma (USC) and clear cell carcinoma (CCC) of the endometrium can be challenging. We undertook an immunohistochemical study to address this issue. METHODS AND RESULTS: We evaluated 401 endometrial carcinomas cases by using four immunomarkers - oestrogen receptor (ER), progesterone receptor (PR), insulin-like growth factor II mRNA - binding protein 3 (IMP3), and intestinal trefoil factor 3 (TFF3)-on a tissue microarray. The cases included 311 EACs (G1, 146; G2, 104; and G3, 61), 69 USCs, and 21 CCCs. ER, PR and TFF3 were most frequently expressed in EACs (P < 0.001), and IMP3 was more frequently expressed in USCs and CCCs (P < 0.001). ER(+) /PR(+) /TFF3(+) /IMP3(-) was the best marker combination associated with EAC [exact odds ratio (OR) 112; 95% confidence interval (CI) 19-∞; P < 0.0001]. This marker combination remained very reliable after adjustment for tumour grade (exact OR 19.2; 95% CI 3-∞; P = 0.0004). Because distinguishing EAC G3 from USC and CCC on the basis of morphology may be difficult, the use of immunomarkers to improve reproducibility is highly recommended. We found the ER(+) /PR(+) /TFF3(+) /IMP3(-) immunoprofile to be the best combination for confirming a diagnosis of endometrioid adenocarcinoma (exact OR 19.2; 95% CI 3-∞; P = 0.0004). CONCLUSIONS: We recommend using an ER/PR/TFF3/IMP3 immunohistochemical panel in selected cases of endometrial carcinoma where the differential diagnosis is challenging.
AIMS: Differentiating endometrioid adenocarcinoma (EAC) from uterine serous carcinoma (USC) and clear cell carcinoma (CCC) of the endometrium can be challenging. We undertook an immunohistochemical study to address this issue. METHODS AND RESULTS: We evaluated 401 endometrial carcinomas cases by using four immunomarkers - oestrogen receptor (ER), progesterone receptor (PR), insulin-like growth factor II mRNA - binding protein 3 (IMP3), and intestinal trefoil factor 3 (TFF3)-on a tissue microarray. The cases included 311 EACs (G1, 146; G2, 104; and G3, 61), 69 USCs, and 21 CCCs. ER, PR and TFF3 were most frequently expressed in EACs (P < 0.001), and IMP3 was more frequently expressed in USCs and CCCs (P < 0.001). ER(+) /PR(+) /TFF3(+) /IMP3(-) was the best marker combination associated with EAC [exact odds ratio (OR) 112; 95% confidence interval (CI) 19-∞; P < 0.0001]. This marker combination remained very reliable after adjustment for tumour grade (exact OR 19.2; 95% CI 3-∞; P = 0.0004). Because distinguishing EAC G3 from USC and CCC on the basis of morphology may be difficult, the use of immunomarkers to improve reproducibility is highly recommended. We found the ER(+) /PR(+) /TFF3(+) /IMP3(-) immunoprofile to be the best combination for confirming a diagnosis of endometrioid adenocarcinoma (exact OR 19.2; 95% CI 3-∞; P = 0.0004). CONCLUSIONS: We recommend using an ER/PR/TFF3/IMP3 immunohistochemical panel in selected cases of endometrial carcinoma where the differential diagnosis is challenging.
Authors: Oluwole Fadare; Vinita Parkash; Katja Gwin; Krisztina Z Hanley; Elke A Jarboe; Sharon X Liang; Charles M Quick; Wenxin Zheng; Kojo R Rawish; Jonathan L Hecht; Mohamed M Desouki Journal: Hum Pathol Date: 2013-10-10 Impact factor: 3.466
Authors: Joyce N Barlin; Robert A Soslow; Megan Lutz; Qin C Zhou; Caryn M St Clair; Mario M Leitao; Alexia Iasonos; Martee L Hensley; Richard R Barakat; Xavier Matias-Guiu; Nadeem R Abu-Rustum Journal: Int J Gynecol Cancer Date: 2013-11 Impact factor: 3.437
Authors: Lien N Hoang; Yow-Shan Lee; Anthony N Karnezis; Basile Tessier-Cloutier; Noorah Almandani; Mackenzie Coatham; C Blake Gilks; Robert A Soslow; Colin J R Stewart; Martin Köbel; Cheng-Han Lee Journal: Histopathology Date: 2016-07-05 Impact factor: 5.087
Authors: Nicole C M Visser; Johan Bulten; Anneke A M van der Wurff; Erik A Boss; Carolien M Bronkhorst; Harrie W H Feijen; Joke E Haartsen; Hilde A D M van Herk; Ineke M de Kievit; Paul J J M Klinkhamer; Brenda M Pijlman; Marc P M L Snijders; Ingrid Vandenput; M Caroline Vos; Peter E J de Wit; Lonneke V van de Poll-Franse; Leon F A G Massuger; Johanna M A Pijnenborg Journal: BMC Cancer Date: 2015-06-30 Impact factor: 4.430
Authors: Kate Lawrenson; Elham Pakzamir; Biao Liu; Janet M Lee; Melissa K Delgado; Kara Duncan; Simon A Gayther; Song Liu; Lynda Roman; Paulette Mhawech-Fauceglia Journal: PLoS One Date: 2015-07-01 Impact factor: 3.240